Literature DB >> 27347076

Treatment effect of cyclosporine A in patients with painful bladder syndrome/interstitial cystitis: A systematic review.

Zhikui Wang1, Lei Zhang1.   

Abstract

Cyclosporine A (CyA) is emerging as a potential therapeutic strategy for painful bladder syndrome/interstitial cystitis (PBS/IC), which is currently an incurable disease. The purpose of this systematic review was to evaluate the treatment effects of CyA in PBS/IC. Electronic and manual retrieval procedures were carried out to identify eligible references for the systematic review. The entire contents of the included articles were assessed, from study design to reported results. Eight studies, comprising three randomized controlled trials (RCTs), four prospective studies and one retrospective cohort study, were included, involving a total of 298 subjects. Meta-analysis was not implemented due to heterogeneity of the manner of reporting the outcome parameters. All studies reported an improvement in symptoms following treatment with CyA. The results of the three RCTs implied that the treatment effects of CyA were better than those of pentosan polysulfate sodium. Some adverse events, for example, elevation of serum creatinine levels and an increase in blood pressure, were noted in five studies. In conclusion, the evidence from the studies implied that treatment of CyA can result in a long-term benefit in patients of PBS/IC; however, further evidence is required to verify this.

Entities:  

Keywords:  cyclosporine A; interstitial cystitis; painful bladder syndrome; systematic review; treatment effect

Year:  2016        PMID: 27347076      PMCID: PMC4906936          DOI: 10.3892/etm.2016.3301

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  17 in total

1.  Cyclosporine A or tacrolimus for hepatitis C recurrence? An old debate.

Authors:  X Forns; M Navasa
Journal:  Am J Transplant       Date:  2011-08       Impact factor: 8.086

2.  Summary of the National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases Workshop on Interstitial Cystitis, National Institutes of Health, Bethesda, Maryland, August 28-29, 1987.

Authors:  J Y Gillenwater; A J Wein
Journal:  J Urol       Date:  1988-07       Impact factor: 7.450

3.  Cyclosporine A and pentosan polysulfate sodium for the treatment of interstitial cystitis: a randomized comparative study.

Authors:  Jukka Sairanen; Teuvo L J Tammela; Mikael Leppilahti; Markku Multanen; Ilkka Paananen; Kari Lehtoranta; Mirja Ruutu
Journal:  J Urol       Date:  2005-12       Impact factor: 7.450

4.  Prevalence of painful bladder symptoms and effect on quality of life in black, Hispanic and white men and women.

Authors:  J Quentin Clemens; Carol L Link; Paul W Eggers; John W Kusek; Leroy M Nyberg; John B McKinlay
Journal:  J Urol       Date:  2007-04       Impact factor: 7.450

Review 5.  Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis.

Authors:  A Maza; H Montaudié; E Sbidian; A Gallini; S Aractingi; F Aubin; H Bachelez; B Cribier; P Joly; D Jullien; M Le Maître; L Misery; M-A Richard; J-P Ortonne; C Paul
Journal:  J Eur Acad Dermatol Venereol       Date:  2011-05       Impact factor: 6.166

6.  Potassium sensitivity test (PST) as a measurement of treatment efficacy of painful bladder syndrome/interstitial cystitis: a prospective study with cyclosporine A and pentosan polysulfate sodium.

Authors:  Jukka Sairanen; Teuvo L J Tammela; Mikael Leppilahti; Markku Onali; Tapio Forsell; Mirja Ruutu
Journal:  Neurourol Urodyn       Date:  2007       Impact factor: 2.696

7.  Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice.

Authors:  H Ogawa; H Kameda; K Amano; T Takeuchi
Journal:  Lupus       Date:  2009-12-01       Impact factor: 2.911

8.  Urinary epidermal growth factor and interleukin-6 levels in patients with painful bladder syndrome/interstitial cystitis treated with cyclosporine or pentosan polysulfate sodium.

Authors:  Jukka Sairanen; Kristina Hotakainen; Teuvo L J Tammela; Ulf-Håkan Stenman; Mirja Ruutu
Journal:  Urology       Date:  2008-04       Impact factor: 2.649

9.  Cyclosporin in rheumatoid arthritis: monitoring for adverse effects and clinically significant drug interactions.

Authors:  B Dijkmans; A Gerards
Journal:  BioDrugs       Date:  1998-12       Impact factor: 5.807

10.  Cyclosporine A for the treatment of refractory nephrotic syndrome with renal dysfunction.

Authors:  Xiang Gao; Yiyi Ma; Lijun Sun; Dongping Chen; Changlin Mei; Chenggang Xu
Journal:  Exp Ther Med       Date:  2013-12-12       Impact factor: 2.447

View more
  4 in total

Review 1.  Efficacy and safety comparison of pharmacotherapies for interstitial cystitis and bladder pain syndrome: a systematic review and Bayesian network meta-analysis.

Authors:  Xing-Peng Di; De-Yi Luo; Xi Jin; Wan-Yu Zhao; Hong Li; Kun-Jie Wang
Journal:  Int Urogynecol J       Date:  2021-02-27       Impact factor: 2.894

2.  Interventions for treating people with symptoms of bladder pain syndrome: a network meta-analysis.

Authors:  Mari Imamura; Neil W Scott; Sheila A Wallace; Joseph A Ogah; Abigail A Ford; Yann A Dubos; Miriam Brazzelli
Journal:  Cochrane Database Syst Rev       Date:  2020-07-30

3.  Inhibition of peptidyl-prolyl cis-trans isomerase B mediates cyclosporin A-induced apoptosis of islet β cells.

Authors:  Xiao Wei; Dan Zhu; Chenchen Feng; Guofang Chen; Xiaodong Mao; Qifeng Wang; Jie Wang; Chao Liu
Journal:  Exp Ther Med       Date:  2018-09-07       Impact factor: 2.447

Review 4.  Management of Bladder Pain Syndrome (BPS): A Practical Guide.

Authors:  Patrick Juliebø-Jones; Karin M Hjelle; Jannike Mohn; Gigja Gudbrandsdottir; Ingunn Roth; Adeel Asghar Chaudhry; Anne Kvåle Bergesen; Christian Beisland
Journal:  Adv Urol       Date:  2022-01-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.